Therapeutic screening in immune cells allows drug developers to identify and test drug candidates that can modulate immune cell function. This assessment is critical for developing effective treatments for various diseases, including cancer and autoimmune disorders. Equally important is that it allows immune safety tests for the drug candidates before clinical trials.
By applying semi-automated methodologies to therapeutic screening in immune cells you can test large numbers of compounds for their ability to modulate immune cell function in high throughput. By incorporating automation in immune cell-based assays, Revvity has developed a platform that increases data robustness and offers multiplex endpoint readouts with additional customizable capabilities that utilize gene editing CRISPR technologies.
In this webinar you will:
- Understand how to integrate immune cell screening in your drug discovery pipeline
- Learn about a new, high-throughput immune-cell analytical platform to expedite therapeutic assessment
- Discover how to link compound screening in immune cells with further functional genomic screening
Speaker: Dr. Isabelle Nett, Cell-based Screening Team Leader – Revvity and Dr. Yuki Kataoka, Scientist – Taiho Pharmaceutical Co.